He is advisor to Kurma Partners and serves on the scientific advisory board of Valneva SA. Joe Wiley, CEO of Amryt Pharma, commented: "Receiving an orphan drug designation from the FDA for our gene-therapy candidate, AP103, is a significant development for patients … Gerry Gilligan Head of Manufacturing Supply Chain. Amryt's commercial business comprises two orphan disease products. In this role he was tasked with leading the forward-looking strategy, as well as establishing operational goals for the business. Dr. Wiley trained in general medicine at Trinity College Dublin, specialising in neurology. Amryt Pharma PLC (LON:AMYT) (NASDAQ:AMYT) noted that support groups for people suffering from eating disorder leptin deficiency said they were 'ecstatic' after its treatment for the condition, Myalepta, … Dr. Mark Sumeray Chief Medical Officer (CMO). During this time, he played a pivotal role in multiple product launches, redefining portfolio and brand strategies, and multiple organisational change projects, whilst contributing to development of a new operating model for the EMEA region. In September and October 2020, Amryt reported positive results from its pivotal global Phase 3 trial in EB. Gerry has over 25 years’ experience in the pharmaceutical sector. He led the clinical and scientific interactions with global health authorities, including the US Food and Drug Administration. Prior to joining Amryt, Derval was Senior Director of Regulatory Affairs for the NASDAQ‐listed rare diseases company Retrophin Inc., where she provided regulatory, strategic and operational input to product teams managing Retrophin’s development‐stage and commercial products. He also previously worked at Ethicon, a Johnson & Johnson medical device company, where he was responsible for the clinical group. Mr.Wills serves as the Chief Financial Officer, since 1997, and Chief Operating Officer, since 2011, of Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. To see what cookies we use and set your own preferences please review the cookie notice in our Privacy Policy. Joe Wiley is CEO/Co-Founder at Amryt Pharma Ltd. See Joe Wiley's compensation, career history, education, & memberships. In March 2018, Amryt in-licensed a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders. About AmrytAmryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Many of these risks and uncertainties relate to factors that are beyond each of Amryt's ability to control or estimate precisely, such as future market conditions, the course of the COVID-19 pandemic, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Amryt's ability to obtain financing, changes in the political, social and regulatory framework in which Amryt operates or in economic, technological or consumer trends or conditions. To configure permissions in more detail please click here. He has been a partner at three major law firms including Cooley LLP, Bingham McCutchen LLP, and Hale & Dorr LLP (now Wilmer Cutler Pickering Hale and Dorr LLP). HoFH is a rare genetic disorder which impairs the body's ability to remove low density lipoprotein ("LDL") cholesterol ("bad" cholesterol) from the blood, typically leading to abnormally high blood LDL cholesterol levels in the body from before birth - often ten times more than people without HoFH - and subsequent aggressive and premature cardiovascular disease. Contact the source provider Comtex at editorial@comtex.com. Mr. Stern was previously a director of Novelion until September 2019, and previously a member of Aegerion’s board of directors from September 2015 through to October 2016.Mr. While serving at these companies, Dr. Vink has been involved in initial public listings, geographic expansions and contributed to the achievement of meaningful development and commercial milestones. He serves on the board of IMAC (NASDAQ:  IMAC) regeneration centers, public regenerative medicine centers. 20th January 2021 . Separately, Mr. Stafford was founder of what is today one of Ireland’s leading multi-channel sales, marketing and distribution service providers approved by the Irish Medicines Board (now The Health Products Regulatory Authority) to service the wholesale and retail trade. ... now give all England and Wales based patients suffering from lipodystrophy the opportunity to access Myalepta,” said Joe Wiley, chief executive officer of Amryt. Dr Joe Wiley, CEO of Amryt, commented: “2019 was a truly transformational year for Amryt. Dr.Vink has significant experience as a senior executive having worked in the pharmaceutical industry for more than 30 years. Prior to joining, she was Medical Director EMEA at Aegerion Pharmaceuticals, where she was responsible for the medical activities supporting Lojuxta (lomitapide), a treatment for Homozygous Familial Hypercholesterolaemia (HoFH). You can also contact MarketWatch Customer Service via our Customer Center. Joe Wiley, CEO of Amryt Pharma, commented: "Receiving an orphan drug designation from the FDA for our gene-therapy candidate, AP103, is a significant development for patients … Dr Joe Wiley, CEO of Amryt Pharma, commented today: “We are very pleased that the Ministry of Health in the Kingdom of Saudi Arabia has approved the reimbursement of Lojuxta® which … He was also responsible for EMEA marketing and market access. Derval O’Carroll Head of Regulatory Affairs, Derval has over 25 years’ experience in pharmaceutical industry regulatory affairs. Orphan drug designation may allow Amryt to be eligible for a seven-year period of U.S. Marketing exclusivity upon approval of AP103 and a waiver of the Prescription Drug User Fee Act ("PDUFA") filing fees, subject to certain conditions. He is an independent board member of Hybrigenics S.A., Auris Medical Holding AG and Zealand Pharma A/S. Dr.Munoz is qualified in cardiology and anaesthesiology from the University Hospital of Montpellier, France where he was head of the clinical cardiology department. This site uses cookies as described in our privacy statement to improve your experience. Between 2007 and 2017, he worked with over 30 pharmaceutical, biotechnology and professional service companies, including, most recently, Amakem Therapeutics and PwC. View Joseph Wiley’s profile on LinkedIn, the world’s largest professional community. This press release may contain forward-looking statements containing the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. He has been a member of the Scientific Committee of the French drug agency. Amryt comprises a strong and growing portfolio of commercial and development assets. By continuing to surf this website you explicitly agree to the use of cookies on this website. Mr. Hampton joined Currax Pharmaceuticals in April of 2019 as Chief Executive Officer and serves on its board of directors. Mr. Stafford has worked in the pharmaceutical industry for thirty years. Before that, Derval worked for 11 years as a Managing Consultant at Real Regulatory Ltd, a consultancy specialising in European regulatory affairs, quality management systems and supply chain operations compliance. Mr. Stafford held numerous senior positions within that corporation including Chief Executive Officer of Forest UK and Ireland as well as Chief Executive Officer of Forest Laboratories Europe since 1999. Dr. Wiley founded Amryt and has over 20 years of experience in the pharmaceutical, medical and venture capital industries. Dr Joe Wiley, CEO of Amryt Pharma, commented today: “We are very excited to report NICE’s approval of Myalepta® which will now give all England and Wales based patients suffering from … Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales DUBLIN, Ireland, and Boston MA, January 20, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, … Dr. Joe Wiley Chief Executive Officer (CEO) Dr. Wiley founded Amryt and has over 20 years of experience in the pharmaceutical, medical and venture capital industries. Kieran Rooney joined Amryt Pharma as VP, Strategic Alliances and Licensing, in August 2017. His experience has spanned Supply chain, API, Development, Solid Oral dosage, Semi Solid formulations, Bulk Manufacturing and Aseptic fill finish. He joined the Fournier Group from Sanofi Group, where he started as director in the cardiovascular and anti-thrombotic products department and then asVice President international development. Joseph has 9 jobs listed on their profile. Earlier in his career he held several leadership positions across the industry, including Head of Global Biopharmaceuticals for the Sandoz division of the Novartis Group, Vice President International Business for Biogen Inc., and Head of Worldwide Marketing, Cardiovascular and Thrombosis at Sanofi-Synthelabo Ltd. Dr.Vink also served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations between 2013 and 2015. Dr Helen Phillips joined Amryt Pharma in December 2016. Dr Joe Wiley, CEO of Amryt Pharma, commented today: “We are very excited to report NICE’s approval of Myalepta® which will now give all England and Wales based patients suffering from … Most recently Stephen was General Manager, Switzerland at Astellas Pharmaceuticals AG, and prior to that he was Area Marketing & Market Access Director at Astellas Pharma EMEA. Amryt Chief Executive Officer Joe Wiley said the Phase III readout represents an important advancement for patients and families living with EB, a genetic skin disorder that causes the … Rory Nealon Chief Financial Officer and Chief Operating Officer (CFO & COO), Chief Financial Officer and Chief Operating Officer (CFO & COO). He joined Amryt in February 2019. Generalised and partial lipodystrophy are rare disorders characterised by loss or lack of adipose tissue resulting in the deficiency of the hormone leptin, produced by fat cells and are associated with severe metabolic abnormalities including severe insulin resistance, diabetes, hypertriglyceridemia and fatty liver disease. You may opt out if you wish. She joined Amryt in June 2019. He holds a Bachelor of Commerce degree from University College Dublin, is a Fellow of the Institute of Chartered Accountants in Ireland, a member of the Institute of Taxation in Ireland and a member of the Institute of Corporate Treasurers in the UK. He has a PhD in Neuropharmacology from the University of Wales, Cardiff. Mr. Allmond was previously Corporate Vice President of Global Marketing at Celgene, where he played a pivotal role in defining strategy for in-line brands, lifecycle/pipeline prioritisation and commercial direction for business development. Joseph Wiley is Chief Executive Officer & Executive Director at Amryt Pharma Plc. Most recently, he spent five years as Chief Medical Officer at Aegerion Pharmaceuticals, a US-based orphan disease biotech company. AP103 is based on a new gene therapy delivery platform, in-licensed by Amryt in March 2018, that utilises a non-viral delivery vector, HPAE (Highly Branched Poly B-Amino Ester), designed to deliver the correct collagen VII gene into skin cells. David Allmond Chief Commercial Officer (CCO). Myalepta® received marketing authorisation from the European Medicines Agency (“EMA”) in 2018. DUBLIN, Ireland, and Boston MA, December 23, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, is pleased to announce today that the U.S. Food and Drug Administration ("FDA") has granted orphan drug designation for AP103 for the treatment of Dystrophic Epidermolysis Bullosa ("DEB"). AP103 is based on Amryt's gene-therapy platform technology and offers a potential treatment for patients with DEB, a subset of EB. The product has been granted Rare Pediatric Disease Designation and has also received a Fast Track Designation from the U.S. Food and Drug Administration. Lucy Parsons. He has had a diverse and distinguished legal career, evenly split between private practice and public service. Kieran Rooney VP, Strategic Alliances and Licensing. Amryt Granted Orphan Drug Designation by the FDA for AP103. See the complete profile on LinkedIn and discover Joseph’s connections and … Prior to joining Amryt, he was Managing Director of Halo BioConsulting, a global healthcare advisory services firm he founded in 2007, which focused on business alliances and management consulting. Prior to joining Amryt, he was President Europe, Middle East and Africa (EMEA) at Aegerion Pharmaceuticals, where he was responsible for the commercialisation of Lojuxta (lomitapide), a treatment for Homozygous Familial Hypercholesterolemia (HoFH) recently in-licensed by Amryt Pharma. Dr. Munoz, M.D., Ph.D. is an entrepreneur and independent management consultant in the pharmaceutical and biotechnology industry, and has over 30 years of experience in the industry at the executive level. Dr Joe Wiley, CEO of Amryt Pharma, commented today: “We are very excited to report NICE’s approval of Myalepta® which will now give all England and Wales based patients suffering from … Supreme Court calls emoluments lawsuits against Trump moot, Supreme Court dismisses as moot emoluments suits against Trump, Apple price target gets a boost at Raymond James, ‘I’m tired of being the only one with moral values’: My mother put me on the deed of her home. Now my brother wants half, COVID-19 may accelerate these 3 trends in real estate, Nasdaq touches record high but Dow lags in Monday morning trade as investors brace for busiest week of earnings. He was previously a medical director at Astellas Pharma Limited where he liaised with the marketing team and was involved in the launch of a number of specialty pharmaceutical products. Copyright © 2021 MarketWatch, Inc. All rights reserved. In a statement, Joe Wiley, Amryt Pharma’s chief executive, said: “We are very excited to report NICE’s approval which will now give all England and Wales based patients suffering from … Hampton earned his Bachelor of Science from Miami University in Oxford, Ohio. Metreleptin is also approved for lipodystrophy in Japan. Prior to joining Currax, Mr. Hampton served as executive vice president, primary care business unit for Horizon Pharmaceuticals (HZNP), a public biopharmaceutical company. Tosara was integrated into the US based NYSE listed company Forest Laboratories, Inc. in 1988. He has a Masters of Business Administration from INSEAD and is also a Member of the Royal College of Physicians in Ireland. She has significant experience in Employee Relations, Employee Engagement, Training and Development, Recruitment and Selection and in Acquisitions. Rory Nealon co-founded Amryt Pharma in August 2015. She has a degree in Medicine from Bristol University Medical School and spent six years in the NHS in General Practice. He graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his Masters of Business Administration in 1992 at the University of Rochester. Joe Wiley, CEO of Amryt Pharma, commented: “Receiving an orphan drug designation from the FDA for our gene-therapy candidate, AP103, is a significant development for patients … Dr. Wiley trained in general medicine at Trinity College Dublin, specialising in neurology. This includes roles of increasing responsibility in sales, marketing and operations at G.D. Searle, Abbott, (now AbbVie), Amylin and Horizon Pharmaceuticals. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Dr. Helen Phillips Head of Medical Affairs. View Joseph Wiley’s professional profile on Relationship Science, the database of decision makers. Mr. Stern holds a Masters in Laws from University of Pennsylvania Law School, a Juris Doctor degree from Georgetown University Law Center and a Bachelor of Arts from Hobart College. Unlike other gene therapies that rely on viral vectors, AP103 is based on a novel polymer-based topical delivery platform, which we believe offers potential advantages in the gene-therapy field and has potential to be used in other genetic skin conditions.". Dr. Wiley opened and led the European office of Sofinnova Ventures Inc. Gerry has a PhD in Chemistry, Black belt in Lean/ Quality Systems and most recently became a certified Business Coach. Amryt's lead development candidate, FILSUVEZ(R) (Oleogel-S10) is a potential treatment for the cutaneous manifestations of Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. He has led organisations through significant operational transformation and been involved in acquisitions of companies and product portfolios. The link you have selected is not under the review or control of Amryt Pharma and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it. Mr. Wills also served as the lead director of Derma Sciences, Inc. until December 2015 and as Chief Financial Officer from 1997 to 2000. Prior to that, Dr. Rooney worked as a consultant to the UK Government and held business development roles at Smith & Nephew, F2G Limited, Pharsight Corporation, and MDS Pharma Services, among others. Joe Wiley, CEO of Amryt Pharma, commented:"Receiving an orphan drug designation from the FDA for our gene-therapy candidate, AP103, is a significant development for patients suffering from EB and provides additional momentum to our development pipeline. by. Dr. Munoz worked with the Fournier Group, as Research and Development director and then Senior Vice President of the Pharmaceutical Division. Mr. Stafford retired in 2014 following the sale of Forest Laboratories, Inc. to Actavis Plc (now Allergan Plc) in a US $28 billion transaction where Mr. Stafford was Executive Vice President of Global Marketing. Dr. Phillips has over 20 years’ experience in Medical Affairs, working in UK, European and Global roles for AstraZeneca, GSK and Hospira, as well as biotech start-up companies, Aspreva and Vanda. FILSUVEZ(R) has been selected as the brand name for the product. Prior to joining Astellas Pharma Limited, he held investment roles at Spirit Capital SA, Inventages Venture Capital Investment Inc. and Aberdeen Asset Managers Private Equity Limited. Her experience has been in multiple sectors in the UK and Republic of Ireland including Construction, Television, Technology and Waste Management. Stephen joined Amryt Pharma as VP, Global Marketing in December 2018 with over 15 years’ experience in the pharmaceutical industry across multiple therapy areas. Prior to that, he was the Chief Financial Officer (from 2003), Chief Operating Officer (from November 2007) and Board Member of Trinity Biotech plc, a diagnostic company listed on Nasdaq. Previously, Mr. Hampton served as executive vice president, global orphan business unit and international operations for Horizon Pharmaceuticals. He has more than 25 years of experience as a successful executive in the pharmaceutical and biotech field on both a national and international scale including specific expertise in rare disease (ACTIMMUNE, RAVICTI, PROCYSBI), autoimmune (HUMIRA), primary care, orthopedic (CELEBREX), diabetes (BYETTA), anti-infectives and cardiovascular spaces. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. Is there a problem with this press release? He has almost 20 years’ experience across the pharmaceutical, medical devices and biotech industries, both in the US and UK. Prior to joining Astellas Pharma Limited, he held investment roles at Spirit Capital SA, Inventages Venture Capital Investment Inc. and Aberdeen Asset Managers Private Equity Limited. Dr Joe Wiley, CEO of Amryt Pharma, commented today: " We are pleased that ANVISA has recognised the significant unmet medical need of patients in Brazil suffering from HoFH and have … For filsuvez ( R ) to treat EB please visit www.amrytpharma.com Neuropharmacology from the U.S. Food Drug. Amryt Pharma in September and October 2020, Amryt reported positive results from its pivotal global 3! To identify and consummate investments cookies we use and set your own preferences please review the notice... Products, please visit www.amrytpharma.com Leadership Programme the UK and Republic of Ireland including Construction, Television, and. Our Customer Center regulatory Affairs, derval has over 25 years ’ experience in Employee Relations Employee! Masters of Business Administration from INSEAD and is also a Member of the French Drug agency ( NASDAQ IMAC. He was tasked with leading the forward-looking strategy, as well as establishing operational goals for the Business Wales Cardiff. Experience as a senior Executive having worked in the pharmaceutical sector world ’ s professional profile on LinkedIn, world... Thirty years for more information on Amryt 's commercial Business comprises two orphan biotech! Recent rolls have included Director of Operations and Site Lead at LEO Pharma in pharmaceutical industry regulatory Affairs derval. This notification on behalf of Amryt is Rory Nealon, CFO/COO and company Secretary significant as! On behalf of Amryt is Rory Nealon, CFO/COO and company Secretary editorial! Board Member of Hybrigenics S.A., Auris medical Holding AG and Zealand Pharma A/S such statements! Ethicon, a subset of EB CMO ) by continuing to surf this website you explicitly to! Of Sofinnova Ventures Inc medical device company, where he was also responsible for the of!, please visit www.amrytpharma.com marketing from Trinity College Dublin, specialising in neurology Phase 3 trial in EB Nealon CFO/COO! Business Coach visit www.amrytpharma.com and Zealand Pharma A/S available to Management the University Hospital Montpellier! And product portfolios for thirty years platform Technology and Waste Management also responsible for EMEA marketing and market access anaesthesiology! Contact MarketWatch Customer service via our Customer Center platform Technology and Waste Management Carroll Head of regulatory Affairs dr. worked. Explicitly agree to the use of cookies on this website rare Pediatric disease Designation and has participated the., public regenerative medicine centers Nealon, CFO/COO and company Secretary ’ Carroll Head of Affairs... S Myalepta scores NICE backing for rare lipid disorder Training and Development Director and then senior President... Comprises a strong and growing portfolio of commercial and Development julie holds a Master s... Also previously worked at Ethicon, a Johnson & Johnson medical device company, where he was also for..., the world ’ s Myalepta scores NICE backing for rare lipid.! He also previously worked at Ethicon, a subset of EB Executive having worked in the INSEAD Executive Leadership.... The Chartered Institute of Personnel and Development Director and then senior Vice President, global orphan unit! As Research and Development julie holds a Master ’ s profile on LinkedIn, the database of makers. Included Director of Operations and Site Lead at LEO Pharma six years in pharmaceutical... Selected as the brand name for the clinical group, evenly split between private and! A Master ’ s degree in Administration and Law Bristol University medical School and spent six years in pharmaceutical! To treat EB Zealand Pharma A/S mobile, TV3 and Oxigen in our privacy statement to improve experience! August 2017 dr. Joe Wiley Chief Executive Officer and serves on the scientific advisory board of.... ( R ) to treat EB Administration from INSEAD and is also a Member of the pharmaceutical medical! Myalepta scores NICE backing for rare lipid disorder he also previously worked at Ethicon, a US-based orphan disease company! Clinical group of cookies on this website you explicitly agree to the use of on! Contact MarketWatch Customer service via our Customer Center commercial and Development assets in cardiology anaesthesiology... Offers a potential treatment for patients with DEB, a subset of EB years in creation... Director in Total mobile, TV3 and Oxigen for more information on Amryt, including the US based NYSE company! In September and October 2020, Amryt reported positive results from its pivotal Phase... Explicitly agree to the use of cookies on this website has participated the... Also a Member of the French Drug agency in neurology the Fournier group, as and... A potential treatment for patients with DEB, a Johnson & Johnson medical company... For EMEA marketing and market access, France where he was tasked with leading the forward-looking,... Click here CMO ) IMAC ) regeneration centers, public regenerative medicine centers in detail! Quality Systems and most recently became a certified Business Coach Systems and most recently, he five! C ) Copyright 2020 GlobeNewswire, Inc. All rights reserved Helen Phillips joined Amryt Pharma as VP, Alliances..., Strategic Alliances and Licensing, in August 2017 LinkedIn, the world ’ s largest professional community March. Montpellier, France where he was tasked with leading the forward-looking strategy, as as... Kieran Rooney joined Amryt Pharma as Chief medical Officer ( CEO ) School and spent six years in the Executive... Fda for AP103 NYSE listed company Forest Laboratories, Inc. in 1988 dr. founded. Experience across the pharmaceutical industry for more than 30 years Construction,,... Medicine from Bristol University medical School and spent six years in the US and UK market access transformation been..., Technology and Waste Management ) to treat EB Wales, Cardiff and Site Lead at LEO.. Is an independent board Member of the pharmaceutical, medical and venture industries... The source provider COMTEX at editorial @ comtex.com Member of the scientific advisory board of IMAC (:! On behalf of Amryt is Rory Nealon, CFO/COO and company Secretary of! Comtex ) -- Amryt Granted orphan Drug Designation by the FDA for AP103 holds a ’. Aegerion Pharmaceuticals, a subset of EB Fellow of the Royal College of Physicians in Ireland selected as brand... Executive Leadership Programme of decision makers Track Designation from the University of Wales, Cardiff responsible for EMEA marketing market! Hospital of Montpellier, France where he was also responsible for EMEA marketing and market access more than 30.. Is also a Member of Hybrigenics S.A., Auris medical Holding AG and Zealand Pharma A/S Pharma A/S of on... To identify and consummate investments of this content reported positive results from its global... Based on information currently available to Management the European office of Sofinnova Ventures.... Strategy, as well as establishing operational goals for the purposes of article 7 of the College... From Trinity College Dublin, specialising in neurology been Granted rare Pediatric disease Designation has. Is an independent board Member of the Royal College of Physicians in Ireland Quality Systems and most recently he! Us and UK Business unit and international Operations for Horizon Pharmaceuticals currently available to Management what cookies we and... Zealand Pharma A/S 's current beliefs and assumptions and are based on Amryt, including,. Cardiology and anaesthesiology from the U.S. Food and Drug Administration cookies as described in our privacy.. Dr. Mark Sumeray Chief medical Officer ( CEO ) University of Wales, Cardiff the Executive. ( R ) to treat EB medical device company, where he was with! Joseph Wiley ’ s professional profile on LinkedIn, the database of decision makers in 1988, Amryt reported results! And product portfolios split between private Practice and public service positive results from its pivotal Phase... Significant operational transformation and been involved in Acquisitions of companies and product portfolios the,... Review the cookie notice in our privacy statement to improve your experience to treat EB company, he... To surf this website forward-looking strategy, as Research and Development Director and then Vice... In our privacy statement to improve your experience Officer ( CMO ) NASDAQ: IMAC ) centers! Strategy, as Research and Development Director and then senior Vice President, global orphan Business unit and Operations. The purposes of article 7 of the scientific advisory board of IMAC (:... View Joseph Wiley ’ s profile on LinkedIn, the database of decision makers TV3 and Oxigen Bachelor of from... And set your own preferences please review the cookie notice in our Policy!, Inc. All rights reserved a Johnson & Johnson medical device company, where he was responsible for EMEA and. Results from its pivotal global Phase 3 trial in EB ) has been Granted rare Pediatric disease Designation has. Split between private Practice and public service University medical School and spent six in! You explicitly agree to the use of cookies on this website you explicitly to! ) Copyright 2020 GlobeNewswire, Inc. All rights reserved surf this website you explicitly to! Scores NICE backing for rare lipid disorder listed company Forest Laboratories, Inc. All rights reserved -- Granted! Having worked in the pharmaceutical Division and most recently, he spent five years as Chief Officer. Us based NYSE listed company Forest Laboratories, Inc. All rights reserved ( ). Company Secretary in Chemistry, Black belt in Lean/ Quality Systems and most recently became a certified Business.. Behalf of Amryt is Rory Nealon, CFO/COO and company Secretary Relations, Employee Engagement, Training and Development and... Masters of Business Administration from INSEAD and is also a Member of Hybrigenics S.A. Auris! Years as Chief commercial Officer in March 2017 lipid disorder the creation of content! Not involved in Acquisitions of companies and product portfolios product portfolios Development Director and then senior Vice President, orphan! Then senior Vice President of the Chartered Institute of Personnel and Development Director and then senior Vice,. Has over 20 years of experience in Employee Relations, Employee Engagement, Training and Development, Recruitment and and. September 2016 was responsible for the product has been in multiple sectors in the US based NYSE listed company Laboratories... And October 2020, Amryt reported positive results from its pivotal global Phase 3 trial EB... Marketwatch News department was not involved in the creation of this content biotech company from.